Skip to main content
. Author manuscript; available in PMC: 2011 Sep 27.
Published in final edited form as: Small. 2011 May 11;7(12):1647–1652. doi: 10.1002/smll.201100012

Figure 3.

Figure 3

MR measurements and imaging of FeCo/C NPs and Resovist. a) Concentration-dependent T2 measurements of FeCo/C NPs and Resovist solutions. b) T2-weighted MR images of various nanoparticle solutions. The FeCo/C NPs show higher MR image contrast (several fold) as compared to Resovist, a traditional MRI contrast agent. c) T2-weighted MR images of a rat before (t = 0 min) and 30 min after (t = 30 min) injection of FeCo/C NPs (left) and Resovist (right) into a rat’s tail vein. The nanoparticles were seen to localize in the liver (green arrow), spleen (blue arrow), and kidneys (red arrow) of the animal. Also, FeCo/C NPs show a higher imaging contrast at a lower concentration (0.25 mg of Fe) as compared to Resovist (2.5 mg of Fe). d) Raman spectra of U87-EGFP cells (marked by arrows) treated with 11-nm FeCo/C NPs. The spectra shows the capability of the FeCo/C NPs to be used as imaging agents at the single-cell level (see Figure S8 in the SI for detailed Raman imaging).